Paul L. M. van Giersbergen

First‐in‐man safety and pharmacokinetics of synthetic ozonide <scp>OZ439</scp> demonstrates an improved exposure profile relative to other peroxide antimalarials

Joerg J. Moehrle, Stephan Duparc, Christoph Siethoff et al. · British Journal of Clinical Pharmacology · 2012 · 116 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

Patricia N. Sidharta, Paul L. M. van Giersbergen, Atef Halabi et al. · European Journal of Clinical Pharmacology · 2011 · 108 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +9

A toxin from the green mamba <i>Dendroaspis angusticeps</i>: Amino acid sequence and selectivity for muscarinic m4 receptors

Mikael Jolkkonen, Paul L. M. van Giersbergen, Ulf Hellman et al. · FEBS Letters · 1994 · 93 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Single‐ and multiple‐dose pharmacokinetics of bosentan and its interaction with ketoconazole

Paul L. M. van Giersbergen, Atef Halabi, Jasper Dingemanse · British Journal of Clinical Pharmacology · 2002 · 87 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +10

Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT₃ receptors

Robert C. Miller, Martin Galvan, Maurice W. Gittos et al. · Drug Development Research · 1993 · 81 citations

Medicine, Neuroscience, Pharmacology +12